Histone methylation is crucial for gene regulation and genetic stability and dysregulation of this process has been observed in many types of cancers. The histone lysine demethylases including the Flavin Adenine Dinucleotide (FAD)-dependent LSD1 (also known as BHC110, AOF2, and KDM1A) and JmjC domain-containing JMJD family are able to specifically remove the methyl groups on histone lysine residues. LSD1 specifically catalyzes removal of methyls of H3K4me1/2 and H3K9me1/2, while the Fe 2+ /2-OG-dependent JmjC domain-containing demethylases demethylate all possible lysine methylation states on histone H3.
LSD1 has shown diverse biological functions, its aberrant overexpression is closely associated with cell proliferation, Epithelial-mesenchymal Transition (EMT), stem cell biology, and malignant transformation of cells, and cell differentiation. LSD1 ablation also stimulates anti-tumor immunity and enables checkpoint blockade. The biological importance of LSD1 makes it a promising therapeutic target for cancer therapy. To date, a large number of LSD1 inhibitors have been identified, some of which (e.g. ORY-1001 in Fig. 1 ) are currently being assessed alone or in combination with other therapeutic agents in clinical trials for the treatment of Acute Myeloid Leukemia (AML) and Small Cell Lung Cancer (SCLC). The success of ORY-1001 makes tranylcypromine (TCP) an attractive scaffold for LSD1 inhibitor design [1, 2] . To date, some high-resolution LSD1 co-crystal structures in complexed with small molecules and peptides have been released, which resulted in the extensive use of X-ray crystallography for designing LSD1 inhibitors. A large number of LSD1 inhibitors have been identified through computational approaches. Based on the reported LSD1 inhibitors and released X-ray co-crystal structures, we tentatively proposed the "2+1" model for the design of new LSD1 inhibitors [3] , which was subsequently utilized to design new LSD1 inhibitors [4] [5] [6] . Generally, the assay procedure for LSD1 screening couples the production of H 2 O 2 from the LSD1 reaction with Horseradish Peroxidase (HRP), the product of which is then captured by Amplex Red. The drawback of this commonly used assay procedure is that compounds with aromatic character often act as HRP inhibitors, giving a false positive reading. This interaction makes it appear that a compound inhibits LSD1, when in fact it only inhibits HRP. Besides, phenolic and/or aniline compounds always consume H 2 O 2 , and then give a false positive reading as well. Some phenolic natural products such as flavones have been reported to inhibit LSD1 in vitro, but these compounds are not fully characterized, thus possible off-target effects could not be excluded. Therefore, a hit compound that inhibits the demethylase activity of LSD1 should be orthogonally validated in enzymatic and cellular levels before further structural modifications. Recently, Cole et al. reported that corin (Fig. 1) , a hybridized compound derived from entinostat (class I Histone Deacetylatse HDAC inhibitor) and tranylcypromine (LSD1 inhibitor), dually inhibited LSD1 and HDAC and showed effective antitumor activity in a melanoma mouse xenograft model [7] . This comprehensive work shows the promise of dual small-molecule inhibitors targeting LSD1 and other therapeutic targets and provided new therapeutic opportunities. We recently disclosed that the third-generation EGFR inhibitor osimertinib could inhibit LSD1 as well [8] . To the best of our knowledge, this is the first report regarding a dual LSD1 and EGFR inhibitor. Osimertinib could be used to design more potent and selective LSD1/EGFR dual inhibitors. We believe that more dual inhibitors with LSD1 inhibition will be reported in the near future.
The Proteolysis-targeting Chimeras (PROTACs) is an emerging and promising technique for protein degradation in drug discovery [9] . In structure, heterobifunctional PROTAC molecules include a ligand targeting the protein of interest (POI), a ligand bound to the E3 ubiquitin ligase (e.g. MDM2, IAP, VHL, and cereblon), and a linker bridging the two ligands. To date, a large number of small-molecule protein degraders have been developed to degrade oncogenic proteins including BET (bromodomain and extra terminal domain) family, Bruton's Tyrosine Kinases (BTKs), and Androgen Receptor (AR) for cancer therapy. Another promising but challenging work is to design LSD1 degraders based on the recently developed PROTACs strategy. So far no LSD1 degraders have been reported and the therapeutic potential of such heterobifunctional PROTAC molecules remains elusive. Therefore, the development of LSD1 protein degraders will be of great interest to the community of medicinal chemistry and chemical biology.
Relative to genetic alterations, epigenetic regulation has also played crucial roles in normal physiological process and disease development. The histone Lysine Specific Demethylase 1 (LSD1) has been found to be implicated in various diseases such as virus infection and cancers, making LSD1 a promising therapeutic target. Thus, the development of small molecules targeting LSD1 has been highly pursued in the last ten years, some TCP-based LSD1 inhibitors are currently being investigated in clinical trials for the treatment of cancers. The tumor development always involves dysregulation of multiple proteins or signaling pathways, dual inhibitors with LSD1 inhibition or combination of LSD1 inhibitors may have polypharmacological effects, thus providing new therapeutic opportunities for cancer patients. It is undoubted that this synergistic strategy will witness success in the near future. Apart from LSD1 inhibition, small-molecule induced LSD1 degradation is a blank field with no LSD1 degraders reported, therapeutic potential of LSD1 degradation is elusive, but deserves to be explored in the future. Here we also would like to highlight the demethylase-independent activity of LSD1, which is also involved in tumor development [10] . Interfering the demethylase-independent activity of LSD1 may offer a new avenue for the treatment of cancers. To conclude, LSD1 is an extremely important therapeutic target, and targeting LSD1 by small molecules will hold promise for cancer therapy.
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